When you eat salt may matter as much as how much

NCT ID NCT04021355

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study tested whether taking salt with breakfast versus dinner changes blood pressure patterns and nighttime salt excretion in 53 obese adults. Participants took salt tablets at different times of day. The goal was to see if timing affects blood pressure rhythms and related health markers. Results could help design better ways to manage hypertension in obesity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral sodium supplementation (salt tablets)
What this could lead to
If it works, this could point toward simple dietary timing strategies to better manage blood pressure in people with obesity.
What could go wrong
This is a small, early-stage study with only 53 participants. It looks at biological patterns, not a proven treatment, so results may not lead to direct health advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Nov 2020

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * obese (BMI 30-50 kg/m2) * 25-45 years of age Exclusion Criteria: * evidence of kidney disease (eGFR \< 60 ml/min/1.73m2 or abnormal urinalysis) * elevated BP (\>150/90 mmHg \[measured at screening in duplicate after 10min lying recumbent\]) * elevated fasting glucose (\>126 g/dL on screening labs) * severe anemia (hemoglobin \< 8 g/dL for women or \< 9 g/dL for men) * significant psychiatric illness (as assessed by a validated screening form) * past or present drug or alcohol abuse (drug screen) * taking 2 or more BP medications or supplements on a regular basis * alcohol intake more than 2 drinks/day * pregnancy * women taking hormone replacement therapy, or post-menopausal women; * shift worker * sleep disorders (such as sleep apnea assessed by Apnea Link) * major chronic disease (e.g., diabetes, lymphocyte disorders) * history of smoking or use of tobacco products within the past year * use of sleep medications, hypnotics, stimulants, or anti-depressants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circadian dysregulation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.